Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

HCG acquires 51% stake in Mahatma Gandhi Cancer Hospital and Research Institute, Vizag

Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility

Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis